37 results about "Interleukin 22" patented technology

The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

This invention discloses the uses of IL-22 in the treatment and prevention of a nerve damage disease or a neurodegenerative disease. In particular, the invention discloses the uses of IL-22 or IL-22 dimers as follows: (i) can protect neurons to recover the functions of injured neurons after ischemic nerve damage in animals in vivo, thus enabling effective treatment of nerve damage diseases, (ii) can significantly inhibit the loss of dopaminergic neurons in substantia nigra in PD model animal, enhance the functions of dopaminergic neurons, significantly reduce neuronal apoptosis in hippocampus, improve learning and memory capacity of AD model rats, and effectively prevent neuronal loss, thereby enabling more effective treatment of neurodegenerative diseases.

The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury)/ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI/ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or signal transducer and activator of transcription 3 (Stat3) and/or Janus kinase 2 (Jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27).

The invention relates to the technical field of biology, and particularly discloses a humanized interleukin-22-resistant genetically engineered antibody and a preparation method and application thereof. By means of the genetic engineering technology and the phage display technology, the antibody capable of being combined with human IL-22 can be directly screened out of a human antibody gene pool, and the antibody gene is obtained and expressed. The antibody can be used for treating autoimmune diseases related to Th17/IL-17 and detecting IL-22.

The invention discloses a vagina injection agent for treating uterine prolapse. The vagina injection agent is prepared from the following components in parts by weight: 5-20 parts of beta-glucan, 1-10parts of lycium barbarum polysaccharide, 1-10 parts of chitosan oligosaccharide, 5-15 parts of recombinant human serum albumin, 0.05-0.5 part of recombinant human interleukin-22, 0.1-0.6 part of recombinant human interleukin-4, 0.3-1.5 parts of a recombinant human epidermal growth factor, 10-15 parts of active lactobacillus powder, 0.1-1 part of a penetration enhancer, 1-5 parts of a bio-adhesiveagent, 40-60 parts of a buffer solution and 50-100 parts of normal saline. The vagina injection agent directly acts on lesion parts, local drug concentration is high, the vagina micro-environment canbe effectively improved, the micro-ecological balance in a vagina and the normal micro-environment of a cervix are maintained, and local and body immune functions are improved; and the vagina injection agent can further promote cell regeneration, promote collagen synthesis, improve skin elasticity, accelerate repair of damaged tissue, promote tension recovery of pelvic floor muscles, fascia and uterus ligament, and can effectively improve uterine prolapse; and recurring is not prone to appearing after cure, using is convenient and safe, and the effect is fast.

The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).

The use of interleukin 17E to inhibit tumour growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumour growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.

The invention provides application of IL22 in the preparation of drugs for improving the production performance of pigs. A DNA sequence of a recombinant porcine interleukin 22 is shown as SEQ ID NO.3.The drugs can be a fermentation broth obtained by eukaryotic fermentation of IL22, or an oral preparation prepared by IL22 combined with a pharmaceutically acceptable auxiliary material or carrier. The food intake of pigs can be significantly increased, the diarrhea rate of pigs can be reduced, so that the feed conversion rate is reduced, and the growth performance of pigs is improved.

The invention belongs to the technical field ofanti-depression drugs, and relates to application of immune cell factor interleukin 22 in preparation ofanti-depression drugs. The anti-depression drug containing the immune cell factor interleukin 22 or the composition thereof has the anti-depression characteristic, is quick in onset time, exact and remarkable in treatment effect and small in side effect, and the immune cell factor interleukin 22 has great application value in research and development of the anti-depression drug and treatment of depression.

The invention discloses preparation and application of a porcine interleukin 17 and 22 co-expression antibiotic-replacing biological preparation. The invention provides a fusion protein. The fusion protein comprises porcine interleukin 17 and porcine interleukin 22. The protein is specifically a protein shown in a sequence 1 or a sequence 3. Nucleic acid molecules encoding the protein also belong to the protection range of the invention. Expression cassettes, recombinant vectors, transfected cells or recombinant microorganisms with the nucleic acid molecules all belong to the protection range of the invention. The invention also provides a culture product of the transfected cell or a fermentation product of the recombinant microorganism. The invention also protects the application of the biological material: preparation of a product for improving animal immunocompetence; improving the animal immunity; preparing a vaccine; resisting pathogenic microorganism infection; the biological material is the protein or the nucleic acid molecule or the expression cassette or the recombinant vector or the transfected cell or the recombinant microorganism or the culture product or the fermentation product.

The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza. In particular, the present invention relates to an interleukin 22 (IL-22) polypeptide for use in the prophylactic treatment of bacterial superinfections post-influenza in a subject in need thereof.

The invention discloses recombinant baculovirus for co-expression of porcine interferon L3 and porcine interleukin 22 by using a baculovirus/insect cell expression system. Indirect immunofluorescence and Western-blot prove that the rPoIFN-L3 and the rPoIL-22, which are co-expressed, can be secreted and expressed in a cell supernatant. The co-expressed rPoIFN-L3 and rPoIL-22 have good biological activity, and can be used for effectively inhibiting the infection of TGEV/PEDV/PDCoV in vitro respectively. In addition, the research finds that the rPoIFN-L3 and the rPoIL-22 have a synergistic anti-TGEV/PEDV effect in vitro when the concentration is 50ng/mL. A large number of rPoIFN-L3 and rPoIL-22 with biological activity can be obtained through the protein expression system, and a foundation is laid for further realization of industrialized preparations for resisting porcine intestinal coronavirus infection.